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Abstract: Background: Screening for invasive anal cancer and its precursors is being increasingly advocated as a re-
sponse to increasing incidence among HIV-infected persons. We implemented a comprehensive screening program in 
2001 and report our early experience to inform monitoring and evaluation of such programs. Our research aims were: (1) 
to estimate incidence of and mortality from invasive anal cancer (IAC) before (1995-2000) and after (2001-2005) screen-
ing program implementation and (2) to examine potential screening program quality indicators. 
Methods: The study cohort included all patients under care for HIV infection at UCSD Owen Clinic between 1995-2005. 
Person-time incidence rates (IR) and case survival of IAC were estimated for the pre-screening (1995-2000) and post-
screening (2001-2005) periods. High resolution anoscopy (HRA) operator accuracy was estimated by kappa agreement 
between cyto-histologic comparisons. Program quality indicators included: (1) screening coverage; (2) percent technically 
unsatisfactory cytology smears; (3) time between 1
st abnormal cytology and 1
st HRA; and (4) time between last clinic visit 
and last cytology. 
Results: 28 cases of IAC and 13,411 person-years were observed between 1995-2005. IRs (95% CI) pre-screening and 
post-screening were 199 and 216 per 100,000 person-years, respectively. There was no routine treatment of high grade 
squamous intraepithelial lesions (HSIL) during the study period. The percent of patients with IAC requiring chemoradia-
tion decreased from 90.9% to 70.6% (p=0.36). There was a significant improvement in cyto-histologic agreement at HRA 
with increasing operator experience (r=0.92, p=0.025). Screening coverage was 73% of the target population. Among 14 
providers, the percent unsatisfactory cytology smears averaged 27% but varied from 0 – 62%. The median time from 1
st 
abnormal cytology to 1
st HRA was 258 days. The median interval between the last cytology and the last clinic visit was 
207 days. 
Conclusions: (1) The overall IR of IAC did not decline in the screening era and was higher than previous estimates for 
HIV cohorts; (2) stage shift to IAC of more favorable prognosis is a reasonable screening goal; (3) HRA accuracy varied 
by provider experience; (4) because of delay in access to HRA, digital rectal exam should be combined with cytology 
screening to detect palpable disease. 
Keywords: Anal dysplasia, screening, HIV. 
BACKGROUND 
  Screening for invasive anal squamous cell carcinoma and 
its precursors has been increasingly advocated in high risk 
populations,  especially HIV infected men having sex with 
men. Although the most recent U.S. Public Health Service 
guidelines  for  prevention  of  opportunistic  infections[1]  do 
not recommend routine screening, the New York State De-
partment  of  Health  AIDS  institute  recently  recommended 
baseline and annual anal cytology examinations with referral 
for high resolution anoscopy and/or biopsy for cytology ab-
normalities  for:  men  who  have  sex  with  men,  any  patient 
with a history of anogenital condylomas, and women with 
abnormal cervical/vulvar histology [2]. The present state of 
knowledge to justify such a screening program was recently 
reviewed [3, 4]. In 2001, we implemented a comprehensive 
screening program for anal cancer and its precursor lesions 
in  the  UCSD  Owen  Clinic,  an  academic  multidisciplinary 
adult HIV clinic in San Diego and have previously presented 
our  observations  regarding  the  prevalence  of  detected 
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abnormalities, their association with degree of immunosup-
pression,  and  the  reproducibility  of  screening  component 
measurements  [5-7].  In  the  current  work,  we  present  pre-
liminary findings regarding implementation of our screening 
program  and  discuss  challenges  to  scientific  evaluation  of 
such a screening program using observational cohort data. 
  Our specific research aims were: (1) to estimate the inci-
dence of invasive anal cancer (IAC) and case-survival before 
(1995-2000) and after (2001-2005) screening program imple-
mentation  and  (2)  to  examine  potential  screening  program 
quality indicators. We hypothesized that screening-prompted 
early surgical intervention for IAC would reduce the incidence 
of IAC requiring treatment with chemoradiation (IACchemorad). 
METHODS 
Incidence Analysis 
  The study cohort included all patients under care for HIV 
infection  between  1995-2005  at  UCSD  Owen  Clinic,  a 
multidisciplinary academic adult HIV clinic. Follow up time 
for each patient began on the date of the first clinic visit dur-
ing the study period or on 1 January 1995 for those already 
under care. Follow up time ended on the date of  the first  
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diagnosis of invasive anal cancer (for those developing the 
outcome) or on the latest of either the date of the last clinic 
visit during the study period or the end of the study period 
(for those with visits after 31 December 2005). During the 
study period, treatment for high grade dysplasia was not rou-
tinely offered. All cases of biopsy confirmed invasive anal 
squamous cell carcinoma were ascertained by review of the 
clinic electronic medical record, review of surgical pathol-
ogy records and the medical center cancer registry. Carci-
noma in situ (CIS) was classified as a precursor lesion, not as 
an outcome. Routine anal cytologic screening of all patients 
under care was implemented as part of a comprehensive anal 
dysplasia screening program in 2001. Routine human papil-
loma  virus  (HPV)  typing  was  not  included  among  the 
screening  procedures.  Person-time  incidence  rates  (IR)  of 
IAC were estimated for the pre-screening (1995-2000) and 
post-screening (2001-2005) periods. Cases of IAC were fur-
ther classified by primary treatment modality (surgical exci-
sion  or  chemoradiation).  Because  no  treatment  for  high 
grade dysplasia was used during the study period, it would 
not be expected that screening per se would reduce the over-
all  incidence  of  IAC.  To  estimate  the  potential  impact  of 
screening  on  IACchemorad,  the  preventive  fractions  in  the 
population and in those exposed to screening were estimated 
for the screening period 2001 – 2005. The preventive frac-
tion for the population (PFp) is defined as the net proportion 
of all potential cases of IACchemorad that would be prevented 
by screening-prompted early surgical intervention. The pre-
ventive fraction among the exposed (PFe) is the net propor-
tion of all potential cases of IACchemorad in the screened popu-
lation that were prevented by screening [8, 9]. Because of 
biases inherent in the estimation of preventive fractions from 
observational studies, we estimated them using two different 
reference rates of IACchemorad in the absence of screening: (1) 
IR 1995 – 2000 and (2) IR unscreened, 2001-2005. 
Case Survival Analysis 
  Kaplan Meier survival was estimated using two alterna-
tive  definitions  of  the  origin  of  time  at  risk  (t0).  In  one 
analysis, t0 was taken as the date of diagnosis of IAC. In the 
alternate analysis, t0 was taken as the date of clinic entry or 
the opening date of the study period (if visits occurred prior 
to that date), irrespective of when subsequently the patient 
was  diagnosed  with  IAC.  These  analyses  were  chosen  to 
illustrate the sensitivity of inference regarding case survival 
to lead time bias and length biased sampling [10]. 
Quality Indicator Analysis 
  Five potential program quality indicators were examined: 
(1) screening coverage; (2) percent technically unsatisfactory 
anal cytology results; (3) cyto-histologic agreement at HRA; 
(4) time delay between first abnormal anal cytology and first 
HRA; (5) time between last clinic visit and last anal cytol-
ogy. Screening coverage is defined in this study as the pro-
portion of the target population screened at least once during 
the screening period [11]. During the study period, cytologic 
specimens  were  obtained  using  the  previously  described 
“blind  sampling”  technique[12]  with  a  moistened  Dacron 
swab  and  conventional  formalin  slide  fixation.  During  the 
study period, the clinic guideline recommended annual anal 
cytologic  examination  for  all  patients[13]  and  referral  to 
HRA for any cytologic abnormality [7]. Because of limited 
availability of trained HRA clinicians, patients were triaged 
to  HRA  according  to  severity  of  the  antecedent  cytologic 
abnormality. For example, a high grade (HSIL) or “atypical 
squamous cells, cannot rule out high grade” (ASC/H) result 
took priority in scheduling over either low grade squamous 
intraepithelial  lesion  (LSIL)  or  atypical  squamous  cells  of 
uncertain significance (ASCUS) results. Quality of individ-
ual clinician performance of anal cytologic examination was 
estimated as the percent of technically unsatisfactory results 
as determined by the reading cytopathologist. Spearman rho 
was calculated to determine if there was an association be-
tween  experience  (number  of  cytologic  specimens  submit-
ted) and the proportion of technically unsatisfactory cytology 
results. HRA operator accuracy as a measure of procedural 
quality  was  estimated  by  calculating  kappa  agreement[14] 
between  the  most  severe  histopathologic  biopsy  diagnosis 
and the concurrent cytology diagnosis obtained at HRA. For 
purposes of kappa agreement analysis, cytology results were 
binary coded as either high grade squamous intraepithelial 
lesion  (HSIL)  or  lesser  abnormality  (including  low  grade 
SIL,  ASCUS  and  “no  atypical  or  malignant  cells”),  and 
histopathologic results were coded as either HSIL (including 
moderate or severe dysplasia or carcinoma) or lesser abnor-
mality. Following revision of the  Bethesda staging system 
for  cervical  cytology  in  2001[15],  an  additional  cytologic 
category  was  created:  atypical  squamous  cells,  cannot  ex-
clude HSIL (ASC/H). This cytologic abnormality was coded 
as HSIL for analysis of cyto-histologic agreement. In order 
to monitor the program so that patients with abnormal results 
are evaluated in a timely fashion, the two measures of proce-
dure delay were examined overall and stratified according to 
severity  of  antecedent  cytologic  diagnosis.  Differences  in 
median procedure delay were evaluated using the Kruskal-
Wallis test. The last examined potential quality indicator was 
program coverage, defined as the proportion of patients un-
der  care  during  the  study  period  that  underwent  anal  cy-
tologic screening at least once. 
  Statistical analyses were performed using Stata 9.2 (Stata 
Corporation,  College  Station,  Texas).  This  study  was  ap-




  The  study  cohort  included  5,083  patients  contributing 
13,411  person-years  (p-y)  at  risk  between  1  January  1995 
and 31 December 2005. Demographic and clinical character-
istics of the study cohort have been previously published [5]. 
The median (IQR) duration of follow up time was 1.8 (0.5 – 
4.7) years. During this period, 28 cases of biopsy confirmed 
IAC were observed, of which 11 were diagnosed in the pre-
screening period (1995-2000) and 17 in the screening period 
(2001-2005). Of the 17 cases diagnosed in the screening pe-
riod, 10 (59 %) had undergone prior anal cytology screening. 
Of the 10 IAC patients who had undergone prior anal cytol-
ogy screening, 2 underwent their first screening less than 6 
weeks prior to the diagnosis of IAC. During the screening 
period, of the 17 IAC cases, the percent with IACchemorad did 
not  vary  by  screening  status  (66.7%  [6/9]  among  the  un-
screened and 75% [6/8] among the screened, exact p=1.0). 
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100,000 person-years) of IAC overall and IACchemorad for the 
pre-screening (1995-2000) and screening (2001 – 2005) pe-
riods.  Also  presented  are  estimated  incidence  rates  among 
the screened patient population at risk. The IAC incidence 
rates  in  the  pre-screening  and  screening  periods  were  199 
and 216 per 100,000 person-years, respectively with an inci-
dence rate ratio (IRR screening/pre-screening) of 1.1 (95% exact CI: 
0.48  –  2.56).  Of  the  28  IAC  cases,  22  (78.6%)  received 
chemoradiation. The proportion receiving chemoradiation in 
the pre-screening period was 90.9 % (10/11) compared with 
70.6 % (12/17) in the screening period (exact p=0.355). The 
incidence  rates  of  IACchemorad  in  the  pre-screening  and 
screening  periods  were  181  and  152  per  100,000  person-
years,  respectively,  with  a  corresponding  IRR  screening/pre-
screening of 0.84 (95% exact CI: 0.33 - 2.17). When incidence 
was estimated only among those who had undergone prior 
anal cytology screening between 2001 - 2005, the incidence 
rates were 126 and 94 for IAC overall and IACchemorad, re-
spectively. 
  The  potential  impact  of  screening  without  treatment  of 
HSIL  lesions  on  incidence  of  IACchemorad  was  estimated  by 
calculating preventive fractions, comparing incidence among 
those screened to those not screened using two different refer-
ence rates for the unscreened population: (1) IR 1995 – 2000 and 
(2) IR unscreened, 2001-2005. The IRR 2001-2005/1995-2000 was 0.52 (95% 
exact CI: 0.16 – 1.58). The corresponding estimated preven-
tive fractions among those exposed to screening (PFe) and in 
the population (PFp) were 0.48 (95% exact CI: -0.58 - +0.84) 
and 0.26, respectively. The IRR  screened/not  screened,  2001-2005 was 
0.24 (95% exact CI: 0.06 - 0.89). The corresponding estimated 
PFe and PFp were 0.76 (95% exact CI: 0.11 - 0.94) and 0.62, 
respectively. 
Case Survival Analysis 
  Figs. (1,2) present Kaplan  Meier survival  estimates for 
the 28 IAC cases, stratified by screening period and screen-
ing  status  (1995-2000  pre-screening,  2001-2005  unscreened,  2001-
2005  screened). In Fig. (1), time at risk (t0) was taken as the 
date of IAC diagnosis. The log rank p-value for equality of 
the three survival curves was 0.03. In Fig. (2), t0 was taken 
as the date of first clinic visit during the study period (or the 
opening of the study period if visits occurred prior to that 
date). The log rank p-value under this assumption was 0.015. 
Under either assumption of origin of risk time, those in the 
pre-screening  period  clearly  faired  the  most  poorly,  while 
any suggestive difference between groups during the screen- 
 
ing period was attenuated by assuming t0 to be at clinic entry 
rather than at IAC diagnosis date. 
Quality Indicator Analysis 
  Overall screening coverage during the screening period 
was  73%.  Fourteen  clinicians  obtained  specimens  for  anal 
cytologic analysis during the study period. The median num-
ber of specimens submitted per provider was 270, varying 
from 45 to 839. Among the 14 clinicians, the median percent 
of specimens read as technically unsatisfactory was 25% but 
varied from 0 – 62% (Fig. 3) with no correlation between the 
number of cytologic specimens submitted by each clinician 
and  the  proportion  of  technically  unsatisfactory  results 
(Spearman rho =-0.0022, p=0.99). 
  Six clinicians performed a total of 1763 high resolution 
anoscopies  between  2001  -  2005.  The  median  number  of 
procedures  per  operator  was  176,  varying  from  16  –  886. 
Overall chance-corrected cyto-histologic agreement (kappa) 
was 0.29, but varied among operators from 0.09 – 0.34. In 
contrast to what was observed for the technical unsatisfac-
tory  cytology  indicator,  there  was  a  definite  relationship 
(Fig.  4)  between  operator  experience  and  kappa  cyto-
histologic agreement (Spearman rho 0.89, p= 0.02). 
  The median interval (range) between first anal cytologic 
examination and first HRA for those with any cytologic ab-
normality was 258 (1 – 1567) days. This interval varied ac-
cording to the severity of the first reported anal cytology: 46 
days  (HSIL  or  ASC/H),  189  days  (LSIL),  and  503  days 
(ASCUS) (Kruskal-Wallis p = 0.0001). The median interval 
(range) between the last anal cytology and the last clinic visit 
was 207 (0 – 1639) days. This interval varied by severity of 
the antecedent anal cytology: 235 days( HSIL or ASC/H), 
433  days  (LSIL),  1305  days  (ASCUS),  and  393  days  (no 
atypical or malignant cells) (Kruskal-Wallis p = 0.0001). 
DISCUSSION 
Is Screening Justified? 
  This description of selected early outcomes and process 
indicators  of  a  comprehensive  screening  program  for  anal 
squamous  cell  carcinoma  in  a  population  of  HIV  infected 
adults under care should be viewed in the context of a gener-
ally accepted framework of screening for chronic diseases. 
Such a framework includes  satisfaction of several require-




Table 1.  Person-Time Incidence Rates of Invasive Anal Cancer (IAC), by Study Period and by Treatment Modality 
 
Pre-Screening Period (1995 – 2000)  Screening Period (2001 – 2005) 
 
Incidence (Per 100,000 Person-Years)  95% CI  Incidence (Per 100,000 Person-Years)  95% CI 
Any IAC  199  110 - 359  216  134 - 347 
Any IAC (screened population only)  N/A  N/A  126  63 - 251 
IAC with chemoradiation  181  97 - 336  152  86 - 268 
IAC with chemoradiation  
(screened population) 
N/A  N/A  94  42 - 210 
IAC with chemoradiation  
(unscreened population) 
N/A  N/A  395  177 - 879 14    The Open AIDS Journal, 2007, Volume 1  Mathews et al. 
   
  Fig. (1). Survival from invasive anal cancer (IAC) diagnosis date. 
 
Fig. (2). Survival from clinic entry. Established Anal Dysplasia Screening Program  The Open AIDS Journal, 2007, Volume 1    15 
 
 
Fig. (3). Proportion of technically unsatisfactory anal cytology results. 
 
Fig. (4). Agreement between anal cytology and anal biopsy histopathology. 
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prevalence; (2) its consequences should be medically impor-
tant;  (3)  an  effective  remedy  should  be  available;  (4)  the 
screening procedures should be simple and safe and should 
have known and acceptable operating characteristics; (5) the 
screening program should be cost-effective, (6) implemen-
table in an equitable manner; and (7) the screening proce-
dures should be acceptable to those screened [16]. Of these 
criteria,  there  is  convincing  epidemiological  evidence  that 
among  HIV-infected  men  having  sex  with  men,  the  inci-
dence of IAC is substantial and increasing [17-20], and that 
its  consequences  in  terms  of  morbidity  and  mortality  are 
medically important [3, 21, 22]. The rates of IAC reported in 
the  current  study,  spanning  the  first  10  years  of  potent 
antiretroviral therapy, are higher than that reported in a co-
hort  of  HIV  infected  patients  observed  during  the  period 
1996-2003 (92 per 100,000) [23] and comparable to a recent 
report of IAC incidence among patients with AIDS living in 
San  Diego  County  between  1996-2000  (144  per  100,000) 
[19]. There is also evidence that screening procedures thus 
far recommended [24], based as they are on the  model of 
cervical  cancer  screening,  are  relatively  simple  and  safe, 
with operating characteristics not dissimilar from those re-
ported for cervical cancer screening [5]. Although the addi-
tion  of  HPV  typing  to  cytology  is  increasingly  associated 
with improved cervical cancer screening program character-
istics [25, 26], its role in screening for anal cancer precur-
sors, especially among HIV infected patients, is uncertain. 
There is some evidence for cost-effectiveness of screening 
for anal cancer precursors, although the results were sensi-
tive  to the  assumed rate of progression from precursor le-
sions to IAC and to the effectiveness of treatment for pre-
cancerous lesions [13]. In the case of cervical carcinoma, the 
most analogous disease process for which screening is uni-
versally  accepted,  the  link  between  precursor  lesions  and 
invasive cancer has been established, justifying these precur-
sor  lesions  as  legitimate  intermediate  targets  for  detection 
and intervention [27-31]. However, the relationship between 
comparable precursor lesions and IAC, while highly likely 
based  on  biological  similarities,  is  less  well  characterized 
[32-34]. In addition, while several treatment modalities have 
been suggested for management of anal squamous intraepi-
thelial lesions (ASIL), none have been demonstrated to alter 
natural history in a conclusive way [3]. We are unaware of 
any published research regarding the acceptability and psy-
chosocial consequences of procedures employed in anal can-
cer screening, but there are published models regarding how 
to address this issue in general and in the context of other 
disease processes [35-37]. Recent survey data suggest  that 
knowledge of the importance of anal cancer, its association 
with HPV, and available screening modalities among those 
at risk may be quite limited [38]. 
  The gold standard for evaluation of screening programs 
is the randomized controlled trial, but observational designs 
including both  case-control and  cohort study designs have 
contributed  to  evaluation  of  screening  strategies  [39,  40]. 
The efficacy of cervical cancer screening programs on inci-
dence  of  and  mortality  from  invasive  cervical  cancer  was 
based  on  observational  cohort  and  ecological  studies  [41, 
42]. Because screening for IAC is increasingly practiced at 
centers treating patients at increased risk for IAC based on 
existing epidemiological studies, it is worthwhile to consider 
how such screening programs could be evaluated and what 
studies should be undertaken to evaluate screening efficacy 
[10, 43]. 
For What Should We Screen? 
  A distinction should be made between screening for pre-
cursor lesions to IAC and screening for early IAC. In the 
case of precursor lesions, using estimates from an overview 
of natural history studies of cervical dysplasia as a model for 
AIN,  the  probability  of  progression  of  CIN  3  to  invasive 
cervical cancer (ICC) averaged 12 % with, however, a 33% 
probability of CIN 3 regressing to less severe lesions [31]. A 
more recent meta-analysis estimated the 6 month transition 
probability of HSIL (including CIN 2 and CIN 3) to ICC to 
be 0.0037 (95% prediction interval: 0.00004 –0.03386) [27]. 
Robust  estimates  of  transition  probabilities  from  HSIL  to 
ICC  for  HIV  infected  women  are  not  available  although 
there is evidence that, relative to women without HIV infec-
tion,  transition  probabilities  from  lower  grade  to  higher 
grade  dysplasia  are  higher,  especially  for  those  with  low 
CD4 count; and regression probabilities from higher to lower 
grade abnormalities were lower [44]. In designing a screen-
ing program that targets identification and treatment of pre-
cursor lesions of ICC or IAC, the number needed to screen 
(NNS) [45, 46] to prevent one targeted outcome (e.g. death, 
IAC,  advanced  IAC)  will  vary  as  a  function  of  transition 
probabilities, accuracy of screening procedures, effectiveness 
of treatment of precursor lesions (including recurrence rates 
and prognosis after treatment). In contrast to screening for 
precursor lesions, screening for early IAC without treatment 
of  precursor  lesions,  although  reducing  the  number  of  pa-
tients  undergoing  intervention  who  may  never  have  pro-
gressed  anyway,  runs  the  risk  of  intervening  too  late  if 
screening intervals are too long or screening procedures less 
than completely accurate. 
Direct and Indirect Measures of Screening Program Suc-
cess 
  Potential outcomes for evaluation of a screening program 
for either precursor lesions or early IAC include, among oth-
ers[10, 47]: (1) overall mortality rate or mortality attributable 
to IAC in the population at risk; (2) incidence of all IAC or 
of  advanced  IAC;  (3)  metrics  of  quality-adjusted  survival 
with IAC; (4) case survival rate; and (5) stage shift in pres-
entation with IAC. Of these potential endpoints, Prorok con-
cluded that “there is only one outcome variable known to be 
valid: the cancer mortality rate”, defined as “the number of 
cancer  deaths  per  unit  of  time,  per  unit  of  population  at 
risk.”[10] The pretreatment prognosis for IAC is determined, 
in part, by TNM stage, location, cell differentiation, and co-
morbid  conditions  including  HIV  related  immunosuppres-
sion [48-51]. Practice guidelines of the National Comprehen-
sive  Cancer  Network  [2]  recommend  initial  local  excision 
for stage T1,N0 (≤ 2 cm diameter, no regional lymph node 
metastases) anal margin carcinomas and chemoradiation for 
T1-2, N0 disease for anal canal carcinomas or anal margin 
carcinomas with positive margins at resection. While it re-
mains controversial whether ablative treatment for precursor 
ASILs should be routinely offered in the absence of random-
ized controlled trial evidence of efficacy in reducing the in-
cidence of invasive disease[52, 53], we would argue that an 
acceptable outcome of a screening program for anal cancer 
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if it would permit primary treatment by local resection and 
spare patients the morbidity associated with chemoradiation. 
Even if chemoradiation was required, detection of invasive 
disease  at  earlier  stages  should  result  in  more  favorable 
prognosis [54, 55]. Such an early stage endpoint  could be 
viewed  as  an  indirect  measure  or  surrogate  marker  of 
screening  efficacy,  resulting  in  a  “shift  (toward  less  ad-
vanced disease) in the stage distribution of cases detected by 
screening  compared  with  clinically  detected  cases.”[16] 
Validation  of  stage  shift  as  an  indirect  outcome  measure, 
however, requires distinguishing prolongation of life due to 
early  treatment  from  simply  extending  the  lead  time  (the 
interval between diagnosis at screening and when it would 
have been detected due to symptoms[47]) with no net gain in 
survival  because  treatment  had  no  effect  on  stage-specific 
prognosis. Stage shift is additionally vulnerable as an end-
point to what has been termed overdiagnosis bias [10] result-
ing  from  the  identification  of  early  stage  invasive  disease 
(e.g.  microinvasive  disease[56])  that  might  not  have  pro-
gressed anyway. 
  Does  the  early  data  from  our  screening  program  show 
any evidence of such a shift toward less advanced disease? 
Only a randomized control trial comparing screening to no 
screening  can  definitively  address  the  question  because  of 
biases inherent in observational studies such as our own. It 
would be expected that initially the overall incidence of IAC 
might increase in the immediate post screening period due to 
earlier detection of prevalent cases and to progression of sub 
clinical to clinical disease among those observed in both the 
pre-screening and screening periods of our study. With re-
gard  to  stage  of  disease  at  presentation,  it  is  likely  that 
screening would tend to detect preferentially early stage dis-
ease with longer pre-clinical durations rather than advanced 
disease that is more likely to present with symptoms. This 
phenomenon  has  been  termed  length-biased  sampling[16, 
57]. Using chemoradiation as a proxy of disease stage, al-
though  we  observed  no  significant  difference  between  the 
proportion of IACchemorad cases comparing screened and not 
screened during the implementation phase of the screening 
program (2001 – 2005), there was a significant difference in 
the  rates  of  IACchemorad  comparing  the  screened  and  not 
screened during the same period (94 vs 395 per 100,000 p-
years). This consideration illustrates the extreme caution that 
must be used in interpreting the statistically significant al-
though likely biased estimate of IRR screened/not screened, 2001-2005 
of 0.24 reported above. The estimates of prevented fractions 
based on the same rates are similarly suspect. The estimates 
of  program  impact  based  on  the  reference  rate  of  IAC-
chemorad,1995-2000 = 181 per 100,000 p-years did not support a 
contention of shift in disease stage due to screening. 
  Case survival has been considered a possible endpoint for 
studies of screening efficacy but its interpretation is subject 
to both lead time bias and length biased sampling [10]. Pro-
rok has maintained that distinguishing real increases in case 
survival attributable to screening from artifactual prolonga-
tions  in  apparent survival due  to these biases  is  “virtually 
impossible”[10].  However,  considering  survival  time  from 
study entry instead of from IAC diagnosis date would tend to 
reduce lead  time bias by assigning all  cases  a comparable 
time at risk origin independent of both screening and diagno-
sis of IAC. However, if patient entry to the clinic was in any 
way  associated  with  risk  of  having  subclinical  IAC,  the 
comparability  of  risk  at  t0  would  be  compromised.  The 
analyses presented in Figs. (1,2) illustrate that the decision 
regarding assignment of t0 in case survival analysis is non-
trivial. 
What Should Be the Screening Interval? 
  Because AIN,  like CIN, is a dynamic process with in-
completely defined natural history and because the sensitiv-
ity of a single cytology and HRA-directed biopsy is too low 
to preclude an important risk of false negative results, repeat 
screening at defined intervals is required. In the only pub-
lished cost-effectiveness study of screening for AIN in HIV 
infected homosexual and bisexual men, Goldie et al. found 
screening annually or every 2 years to be cost-effective, al-
though the results were sensitive to the rate of progression of 
ASIL to invasive cancer and to the effectiveness of treatment 
[13]. It is important to note that one of the assumptions of 
their model was that there was no shift to earlier stage dis-
ease  as  a  result  of  screening.  After  a  negative  baseline 
screening procedure, the incidence of IAC will increase due 
to false negative screening tests and development of de novo 
disease. In the case of cervical cancer screening programs, 
two  baseline  cytology  examinations  are  recommended  to 
reduce the false negative rate. The incidence curve after one 
or more negative baseline screenings will be a measure of 
the duration of the detectable preclinical phase of disease, 
the sojourn time [58]. Both case-control and cohort studies 
have been performed to estimate optimal re-screening inter-
val  [59].  The  definition  of  a  negative  screen  is  itself  not 
straight forward when the screening test result can be viewed 
as  either  continuous (e.g. PSA test for prostate  cancer) or 
ordinal  (as  in  cervical  and  anal  cancer  screening).  Taking 
into account the imperfect operating characteristics of both 
cytology and HRA as screening modalities and the cytology 
trigger used to refer for HRA (e.g. ASCUS or more abnor-
mal), several combinations of results could define negative 
tests  (e.g.  2  negative  cytologies  or  ASCUS  cytology  with 
negative HRA). An additional complication, as in our study, 
is the limited duration of follow up of individual patients in a 
dynamic cohort. In our study, the median time at risk was 1.8 
years,  so  estimating  rates  of  incident  cancer  at  increasing 
times after a negative baseline screen becomes less precise as 
fewer  patients  are  under  observation.  The  results  we  have 
presented, however, are based on being screened one or more 
times during the follow up period and therefore cannot di-
rectly  address  the  important  issue  of  optimal  re-screening 
interval.  Other  programmatic  concerns  regarding  re-
screening relate to the follow up of patients already known to 
have abnormal cytology. In the same clinic population, we 
showed that the prevalence of AIN 3 at HRA-directed biopsy 
was 21% and 27% for ASCUS and LSIL cytology results 
[5]. Evidence-based guidance regarding optimal frequency of 
interval  examination  for  those  with  abnormal  cytology  is 
lacking. 
Metrics of Screening Program Quality 
  Separate  from  consideration  of  screening  program  out-
come indicators, the ultimate success of screening programs 
depends on how they are implemented and hence on process 
indicators  of  program  quality.  Such  indicators  include  the 
achieved coverage rate of the target population, maintenance 
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measures of delay and access to both screening and treatment 
modalities.  Although  we  achieved  an  overall  coverage  of 
73% for at least one anal cytology screening,  close to the 
80%  benchmark  accepted  for  cervical  cytology  screen-
ing[60], there was a substantial delay in access to high reso-
lution anoscopy especially for those with lower degrees of 
cytologic  abnormality.  This  delay  was  attributable  both  to 
limited availability of trained HRA operators and to high “no 
show” rates among scheduled patients. In addition, the inter-
val between  last  anal cytology and last clinic visit can be 
interpreted  as  an  additional  indicator  of  program  fidelity. 
The clinic guideline is annual cytology screening for all pa-
tients and this target was approximately achieved for all cy-
tology result categories except for ASCUS (median interval 
1305  days).  Previous  research  from  the  study  clinic  esti-
mated that the prevalence of AIN 3 at biopsy among those 
with ASCUS cytology was 21%[5], both justifying referral 
for HRA and indicating the advisability of regular follow up 
of such patients. The optimal frequency for repeat screening 
to reduce important IAC-related endpoints has not been de-
termined and likely depends on factors similar to those re-
ported for cervical cancer: the duration of pre-clinical dis-
ease,  the  progression  and  regression  rates  of  precursor  le-
sions, the sensitivity of and costs associated with screening 
tests,  and  the  stage-specific  curability  of  detected  disease 
[61, 62]. In the case of HIV-infected patients, there is evi-
dence that progression rates to high grade cervical and anal 
SIL  are  higher  than  among  uninfected  patients,  and  that 
among  HIV  infected  patients,  progression  rates  are  higher 
among the immunosuppressed [63, 64]. In addition, there is 
evidence that the pathogenesis of the transition from AIN 3 
to ICC  may differ  according to HIV infection status [32]. 
Therefore  optimal  SIL  stage-specific  screening  frequency 
will likely differ according to these risk factors for progres-
sion. 
  With regard to ongoing assessment of clinician technical 
performance of screening procedures, we examined the per-
cent technically unsatisfactory cytology results as a measure 
applicable to all primary care providers in the clinic and the 
agreement between cytology diagnostic category and histo-
pathologic diagnosis as an indicator of high resolution ano-
scopist technical quality. As Fig. (3) demonstrates, there was 
substantial and clearly unacceptable variability in the propor-
tion  of  technically  unsatisfactory  cytology  specimens  ob-
tained  by  our  fourteen  primary  care  providers.  Switching 
from conventional slide cytology preparation to liquid media 
offers  a  technology-based  approach  to  reducing  both  the 
variability and rate of unsatisfactory results[65, 66], but on-
going monitoring and training is required to regain an overall 
technically unsatisfactory rate of 6%[5], that observed during 
the early period of program implementation at our clinic. 
  With regard to technical performance of high resolution 
anoscopists,  we  evaluated  cyto-histologic  agreement  as  a 
quality  indicator  and  demonstrated  a  positive  relationship 
between operator experience and kappa agreement. We be-
lieve this metric of chance-corrected agreement [14, 67] can 
be used to compare performance of HRA operators whose 
patient populations may differ in prevalence of high grade 
lesions. An alternative indicator, agreement between visual 
impression and histology, has been evaluated in the context 
of  cervical  colposopic  accuracy  using  the  Reid  index[68], 
which has not been validated for use in high resolution ano-
scopy. We are aware of only one publication providing esti-
mates of predictive value of high resolution anoscopic visual 
findings (e.g. punctation and mosaicism) for high grade dys-
plasia  on  biopsy  [69].  Standards  for  proficiency  in  HRA 
have not been established. However, based on precedent for 
training and evaluation of competency in the performance of 
colposcopy, formal didactic training followed by a clinical 
mentorship  involving  supervised  performance  of  25  –  50 
procedures and including at least 10 HSIL cases would be 
reasonable [70, 71]. Recently the American Society for Col-
poscopy  and  Cervical  Pathology  (ASCCP)  has  offered 
courses  in  performance  of  HRA  (http://www.asccp.org/in-
dex.html). 
  A number of limitations of our analysis, particularly with 
regard  to  the  potential  biases  in  estimating  IAC  incidence 
rates in the two study periods and their associated preventive 
fractions, as well as the limited duration of follow up, have 
been  discussed  above.  Additional  limitations  include:  (1) 
incomplete case ascertainment as a result of loss to follow 
up;  (2)  possible  selection  bias  in  offering  and  accepting 
screening; and (3) possible overdiagnosis bias if some of the 
early stage IAC cases may not have progressed. The analyses 
were  presented  to  illustrate  approaches  to  evaluation  of 
evolving screening programs for IAC and its precursor le-
sions in HIV-infected patient populations. 
CONCLUSIONS 
  We believe that there is insufficient evidence at the pre-
sent time to recommend comprehensive screening with cy-
tology followed by referral for HRA and then ablative treat-
ment of high grade lesions as a general practice guideline. It 
must  be  recognized  that  such  a  comprehensive  approach, 
modeled  as  it  is  on  the  highly  successful  cervical  cancer 
screening paradigm, could not be widely implemented in the 
current  environment  because  of  very  limited  numbers  of 
trained HRA operators who would have to split their time 
between diagnostic and therapeutic procedures. The utility of 
adjunctive reflex anal HPV testing as a screening component 
in HIV infected populations, while recommended for cervi-
cal ASCUS, is an open research question for which minimal 
data is available [72]. However, while awaiting further evi-
dence  that  treatment  of  precursor  lesions  favorably  alters 
natural history at acceptable costs, a more limited screening 
program could be advocated in contrast to doing nothing to 
detect potentially curable IAC in populations at known high 
risk. Such a limited program might involve routine cytology 
screening  accompanied  by  digital  rectal  examinations  and 
referral either to HRA or a surgeon for any palpable lesions, 
bleeding, or other anorectal symptoms. 
ACKNOWLEDGEMENTS 
  This work was supported in part by the UCSD Center for 
AIDS Research (AI 36214) and the CFAR-Network of Inte-
grated Clinical Sciences (AI067039). 
  This work was presented in part at the 13
th Conference on 
Retroviruses and Opportunistic Infections, Denver, Feb 5-8, 
2006, Abstract 808 
  CM was  involved  in all phases of the research project 
and  wrote  the  first  draft  of  the  manuscript.  EC  conducted 
medical record review to determine outcomes of study pa-
tients.  JC  and  BC  performed  medical  and  surgical  proce-Established Anal Dysplasia Screening Program  The Open AIDS Journal, 2007, Volume 1    19 
dures reported in the manuscript. All authors have reviewed 
and approved the final manuscript. 
REFERENCES 
[1]  Masur H, Kaplan JE, Holmes KK. Guidelines for preventing oppor-
tunistic  infections  among  HIV-infected  persons--2002.  Recom-
mendations of the U.S. Public Health Service and the Infectious 
Diseases Society of America. Ann Intern Med 2002; 37(5 Pt 2): 
435-78. 
[2]  Human Papilloma Virus. [Guideline]: New York State Department 
of Health AIDS Institute; 2007 [updated 2007; cited 2007 2 No-
vember]; Available from: http: //www.hivguidelines.org/Guideline 
Documents/a-hpv.pdf. 
[3]  Chiao  EY,  Giordano  TP,  Palefsky  JM,  Tyring  S,  El  Serag  H. 
Screening  HIV-infected  individuals  for anal  cancer precursor  le-
sions: a systematic review. Clin Infect Dis 2006; 43(2): 223-33. 
[4]  Anderson JS, Vajdic C, Grulich AE. Is screening for anal cancer 
warranted in homosexual men? Sex Health 2004; 1(3): 137-40. 
[5]  Mathews WC, Sitapati A, Caperna JC, Barber RE, Tugend A, Go 
U. Measurement characteristics of anal cytology, histopathology, 
and high-resolution anoscopic visual impression in an anal dyspla-
sia screening program. J Acquir Immune Defic Syndr 2004; 37(5): 
1610-5. 
[6]  Mathews C, Mar-Tang M, Smith D, Saville W, Cosman B. Repro-
ducibility and outcomes of anal dysplasia screening in an HIV pri-
mary care clinic (Abstract 605-W). 9th Conference on Retroviruses 
and Opportunistic Infections, Seattle, Wash. Foundation for Retro-
virology and Human Health; 2002. 
[7]  Mathews WC. Screening for anal dysplasia associated with human 
papillomavirus. Top HIV Med 2003; 11(2): 45-9. 
[8]  Greenland  S,  Robins  JM.  Conceptual  problems  in  the  definition 
and interpretation of attributable fractions. Am J Epidemiol 1988; 
128(6): 1185-97. 
[9]  Stata. Stata Reference Manual Release 7, Volume 1 A-G. College 
Station, Texas: Stata Press; 2001. 
[10]  Prorok PC. Epidemiologic approach for cancer screening. Problems 
in design and analysis of trials. Am J Pediatr Hematol Oncol 1992; 
14(2): 117-28. 
[11]  Bos AB, van Ballegooijen M, van Gessel-Dabekaussen AA, Hab-
bema JD. Organised cervical cancer screening still leads to higher 
coverage  than  spontaneous  screening  in  The  Netherlands.  Eur  J 
Cancer 1998; 34(10): 1598-601. 
[12]  Vajdic  CM,  Anderson  JS,  Hillman  RJ,  Medley  G,  Grulich  AE. 
Blind sampling is superior to anoscope guided sampling for screen-
ing  for  anal  intraepithelial  neoplasia.  Sexually  transmitted  infec-
tions 2005; 81(5): 415-8. 
[13]  Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, 
Palefsky JM. The clinical effectiveness and cost-effectiveness of 
screening for anal squamous intraepithelial lesions in homosexual 
and bisexual HIV-positive men. JAMA 1999; 281(19): 1822-9. 
[14]  Cohen  J.  A  coefficient  of  agreement  for  nominal  scales.  Educa-
tional and Psychological Measurement 1960; 20: 37-46. 
[15]  Solomon D, Nayar R, editors. The Bethesda System for Reporting 
Cervical Cytology. Second ed. New York: Springer; 2004. 
[16]  Strong K, Wald N, Miller A, Alwan A. Current concepts in screen-
ing  for  noncommunicable  disease:  World  Health  Organization 
Consultation Group Report on methodology of noncommunicable 
disease screening. J Med Screen 2005; 12(1): 12-9. 
[17]  Chiao  EY,  Krown  SE,  Stier  EA,  Schrag  D.  A  population-based 
analysis of temporal trends in the incidence of squamous anal canal 
cancer in relation to the HIV epidemic. J Acquir Immune Defic 
Syndr 2005; 40(4): 451-5. 
[18]  Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer 
S. The impact of highly active antiretroviral therapy on non-AIDS-
defining cancers among adults with AIDS. Am J Epidemiol 2007; 
165(10): 1143-53. 
[19]  Diamond C, Taylor TH, Aboumrad T, Bringman D, Anton-Culver 
H. Increased incidence of squamous cell anal cancer among men 
with AIDS in the era of highly active antiretroviral therapy. Sex 
Transm Dis 2005; 32(5): 314-20. 
[20]  Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Dal-
ing JR. Anal cancer incidence and survival: the surveillance, epi-
demiology, and end results experience, 1973-2000. Cancer 2004; 
101(2): 281-8. 
[21]  Jephcott  CR,  Paltiel  C,  Hay  J.  Quality  of  life  after  non-surgical 
treatment of anal carcinoma: a case control study of long-term sur-
vivors. Clin Oncol (R Coll Radiol) 2004; 16(8): 530-5. 
[22]  Pachler J, Wille-Jorgensen P. Quality of life after rectal resection 
for cancer, with or without permanent colostomy. Cochrane Data-
base Syst Rev 2004: CD004323. 
[23]  Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal 
cancer:  has  highly  active  antiretroviral  therapy  reduced  the  inci-
dence  or  improved  the outcome?  J  Acquir  Immune  Defic  Syndr 
2004; 37(5): 1563-5. 
[24]  Chin-Hong PV, Palefsky JM. Natural history and clinical manage-
ment of anal human papillomavirus disease in men and women in-
fected with human immunodeficiency virus. Clin Infect Dis 2002; 
35(9): 1127-34. 
[25]  Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papil-
lomavirus  DNA  versus  Papanicolaou  screening  tests  for  cervical 
cancer. N Engl J Med 2007; 357(16): 1579-88. 
[26]  Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and 
Papanicolaou  tests  to  screen  for  cervical  cancer.  N  Engl  J  Med 
2007; 357(16): 1589-97. 
[27]  Cantor SB, Atkinson EN, Cardenas-Turanzas M, Benedet JL, Fol-
len M, MacAulay C. Natural history of cervical intraepithelial neo-
plasia: a meta-analysis. Acta Cytol 2005; 49(4): 405-15. 
[28]  Holowaty P, Miller AB, Rohan T, To T. Natural history of dyspla-
sia of the uterine cervix. J Natl Cancer Inst 1999; 91(3): 252-8. 
[29]  Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural 
history  of  cervical  squamous  intraepithelial  lesions:  a  meta-
analysis. Obstet Gynecol 1998; 92(4 Pt 2): 727-35. 
[30]  Mitchell MF, Hittelman WN, Hong WK, Lotan R, Schottenfeld D. 
The natural history of cervical intraepithelial neoplasia: an argu-
ment  for  intermediate  endpoint  biomarkers.  Cancer  Epidemiol 
Biomarkers Prev 1994; 3(7): 619-26. 
[31]  Ostor AG. Natural history of cervical intraepithelial neoplasia: a 
critical review. Int J Gynecol Pathol 1993; 12(2): 186-92. 
[32]  Gervaz  P,  Hirschel  B,  Morel  P.  Molecular biology  of  squamous 
cell carcinoma of the anus. Br J Surg 2006; 93(5): 531-8. 
[33]  Zbar AP, Fenger C, Efron J, Beer-Gabel M, Wexner SD. The pa-
thology  and  molecular  biology  of  anal  intraepithelial  neoplasia: 
comparisons with cervical and vulvar intraepithelial carcinoma. Int 
J Colorectal Dis 2002; 17(4): 203-15. 
[34]  Scholefield JH, Castle MT, Watson NF. Malignant transformation 
of high-grade anal intraepithelial neoplasia. Br J Surg 2005; 92(9): 
1133-6. 
[35]  Brodersen J, McKenna SP, Doward LC, Thorsen H. Measuring the 
psychosocial  consequences  of  screening.  Health  Qual  Life  Out-
comes 2007; 5: 3. Available at: http: //www.hqlo.com/content/5/1/3 
[36]  Croyle RT. Psychosocial Effects of Screening for Disease Preven-
tion and Detection. New York: Oxford University Press US; 1995. 
[37]  Shinn E, Basen-Engquist K, Le T, et al. Distress after an abnormal 
Pap smear result: scale development and psychometric validation. 
Prev Med 2004; 39(2): 404-12. 
[38]  Pitts  MK, Fox C, Willis J, Anderson J. What do gay men know 
about human papillomavirus? Australian gay men's knowledge and 
experience  of  anal  cancer  screening  and  human  papillomavirus. 
Sex Transm Dis 2007; 34(3): 170-3. 
[39]  Vernon SW, Briss PA, Tiro JA, Warnecke RB. Some methodologic 
lessons  learned  from  cancer  screening  research.  Cancer  2004; 
101(5 Suppl): 1131-45. 
[40]  Prorok  PC.  Mathematical  models  and  natural  history  in  cervical 
cancer screening. IARC Sci Publ 1986; 76: 185-98. 
[41]  Gardner JW, Lyon JL. Efficacy of cervical cytologic screening in 
the control of cervical cancer. Prev Med 1977; 6(4): 487-99. 
[42]  Guzick DS. Efficacy of screening for cervical cancer: a review. Am 
J Public Health 1978; 68(2): 125-34. 
[43]  Parkin  DM,  Day  NE.  Evaluating  and  planning  screening  pro-
grammes. IARC Sci Publ 1985; 66: 45-63. 
[44]  Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cer-
vical squamous intraepithelial lesions in human immunodeficiency 
virus  (HIV)-seropositive  and  at-risk  HIV-seronegative  women.  J 
Infect Dis 2003; 188(1): 128-36. 
[45]  Boomsma LJ, van Lidth de Jeude CP. 'Number needed to screen': a 
tool  for  assessment  of  prevention  programs.  Ned  Tijdschr 
Geneeskd 2000; 144(49): 2345-8. 
[46]  Rembold CM. Number needed to screen: development of a statistic 
for disease screening. BMJ (Clinical research ed) 1998; 317(7154): 
307-12. 20    The Open AIDS Journal, 2007, Volume 1  Mathews et al. 
[47]  Alibhai SM. Cancer screening: the importance of outcome meas-
ures. Crit Rev Oncol Hematol 2006; 57(3): 215-24. 
[48]  Hill J, Meadows H, Haboubi N, Talbot IC, Northover JM. Patho-
logical staging of epidermoid anal carcinoma for the new era. Colo-
rectal Dis 2003; 5(3): 206-13. 
[49]  Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R. The 
significance of pretreatment CD4 count on the outcome and treat-
ment tolerance of HIV-positive patients with anal cancer. Int J Ra-
diat Oncol Biol Phys 1999; 44(1): 127-31. 
[50]  Kauh J, Koshy M, Gunthel C, Joyner MM, Landry J, Thomas CR, 
Jr. Management of anal cancer in the HIV-positive population. On-
cology (Williston Park) 2005; 19(12): 1634-8. 
[51]  Uronis  HE,  Bendell  JC.  Anal  cancer:  an  overview.  Oncologist 
2007; 12(5): 524-34. 
[52]  Devaraj B, Cosman BC. Expectant management of anal squamous 
dysplasia in patients with HIV. Dis Colon Rectum 2006; 49(1): 36-
40. 
[53]  Goldstone S. A stand against expectant management of anal dys-
plasia. Dis Colon Rectum 2006; 49(10): 1648-9. 
[54]  Ortholan C, Ramaioli A, Peiffert D, et al. Anal canal carcinoma: 
early-stage tumors < or =10 mm (T1 or Tis): therapeutic options 
and original pattern of local failure after radiotherapy. Int J Radiat 
Oncol Biol Phys 2005; 62(2): 479-85. 
[55]  Rousseau DL, Jr., Thomas CR, Jr., Petrelli  NJ, Kahlenberg MS. 
Squamous  cell  carcinoma  of  the  anal  canal.  Surg  Oncol  2005; 
14(3): 121-32. 
[56]  Kagawa R, Yamaguchi T, Furuta R. Histological features of human 
papilloma virus 16 and its association with the development and 
progression of anal squamous cell carcinoma. Surg Today 2006; 
36(10): 885-91. 
[57]  Gordis L. Evaluating the evidence for the effectiveness of preven-
tion. J Gen Intern Med 1990; 5(5 Suppl): S14-6. 
[58]  Screening for squamous cervical cancer: duration of low risk after 
negative results of cervical cytology and its implication for screen-
ing policies. IARC Working Group on evaluation of cervical cancer 
screening programmes. Br Med J (Clin Res Ed) 1986; 293(6548): 
659-64. 
[59]  Weiss NS, Etzioni R. Estimating the influence of rescreening inter-
val on the benefits associated with cancer screening: approaches 
and limitations. Epidemiology 2002; 13(6): 713-7. 
[60]  ACCP.  Planning  and  Implementing  Cervical  Cancer  Prevention 
and Control Programs: A Manual for Managers. Seattle: Alliance 
for Cervical Cancer Prevention; 2004. 
[61]  Miller MG, Sung HY, Sawaya GF, Kearney KA, Kinney W, Hiatt 
RA. Screening interval and risk of invasive squamous cell cervical 
cancer. Obstet Gynecol 2003; 101(1): 29-37. 
[62]  Morrison  AS.  Screening  in  Chronic  Disease.  Second  ed.  New 
York: Oxford University Press; 1992. 
[63]  Nappi L, Carriero C, Bettocchi S, Herrero J, Vimercati A, Putig-
nano G. Cervical squamous intraepithelial lesions of low-grade in 
HIV-infected women: recurrence, persistence, and progression, in 
treated and untreated women. Eur J Obstet Gynecol Reprod Biol 
2005; 121(2): 226-32. 
[64]  Palefsky  JM,  Holly  EA,  Hogeboom  CJ,  et  al.  Virologic,  immu-
nologic, and clinical parameters in the incidence and progression of 
anal  squamous  intraepithelial  lesions  in  HIV-positive  and  HIV-
negative  homosexual  men.  J  Acquir  Immune  Defic  Syndr  Hum 
Retrovirol 1998; 17(4): 314-9. 
[65]  Shield  PW,  Nolan  GR,  Phillips  GE,  Cummings  MC.  Improving 
cervical cytology screening in a remote, high risk population. Med 
J Aust 1999; 170(6): 255-8. 
[66]  Abulafia  O,  Pezzullo  JC,  Sherer  DM.  Performance  of  ThinPrep 
liquid-based cervical cytology in comparison with conventionally 
prepared Papanicolaou smears: a quantitative survey. Gynecol On-
col 2003; 90(1): 137-44. 
[67]  Viera AJ, Garrett JM. Understanding interobserver agreement: the 
kappa statistic. Fam Med 2005; 37(5): 360-3. 
[68]  Ferris  DG,  Litaker  MS.  Prediction  of  cervical  histologic  results 
using an abbreviated Reid Colposcopic Index during ALTS. Am J 
Obstet Gynecol 2006; 194(3): 704-10. 
[69]  Jay N, Berry JM, Hogeboom CJ, Holly EA, Darragh TM, Palefsky 
JM.  Colposcopic appearance of anal squamous intraepithelial le-
sions:  relationship  to  histopathology  Dis  Colon  Rectum  1997; 
40(8): 919-28. 
[70]  Brotzman GL, Apgar BS. Assessing colposcopic skills: the instruc-
tor's handbook. Fam Med 1998; 30(5): 350-5. 
[71]  Spitzer  M,  Apgar  BS,  Brotzman  GL,  Krumholz  BA.  Residency 
training in colposcopy: a survey of program directors in obstetrics 
and gynecology and family practice. Am J Obstet Gynecol 2001; 
185(2): 507-13. 
[72]  Walts AE, Thomas P, Bose S. Anal cytology: is there a role for 
reflex HPV DNA testing? Diagn Cytopathol 2005; 33(3): 152-6. 
 
 
Received: October 17, 2007  Revised: October 31, 2007  Accepted: November 5, 2007 
 
 